Literature DB >> 12661472

Utilisation of malaria prophylaxis: the effect of changes in guidelines in The Netherlands, 1993-1998.

Melanie M van Riemsdijk1, Miriam C J M Sturkenboom, Herbert J Schilthuis, Bruno H Ch Stricker.   

Abstract

INTRODUCTION: The increase in international travelling from temperate zones to tropical countries and increasing drug resistance of Plasmodium falciparum has resulted in a growing number of travellers that are at risk for contracting malaria. The objective of this study was to obtain insight into dispensing patterns of malaria chemoprophylaxis and to determine whether health care providers have followed changes in guidelines.
METHODS: Data on prescriptions of proguanil and mefloquine were obtained from the Dutch 'Foundation for Pharmaceutical Statistics' (SFK) covering the period 1 January 1993 up to 31 December 1998. From Statistics Netherlands (SN), we obtained the number of travellers to endemic areas during the years 1994-1998.
RESULTS: There were 420,963 prescriptions for mefloquine and 464,904 for proguanil dispensed during the study period. The total number of prescriptions for malaria chemoprophylaxis increased during the period 1993-1997 from 98,325 (of which 14,427 (14.7%) for mefloquine and 83,898 (85.3%) for proguanil) to 168,452 (of which 90,232 (53.6%) for mefloquine and 78,220 (46.4%) for proguanil). The number of prescriptions per 1000 travellers decreased over the years for proguanil from 169 to 118 but remained stable for mefloquine at 126. The average duration for which mefloquine was prescribed remained stable, whereas the average duration for which proguanil was prescribed decreased over time. We observed differences in the prescription rate of prescriptions for mefloquine between geographical regions in the Netherlands.
CONCLUSION: Changes in the guidelines of malaria prophylaxis with respect to type and duration were generally followed by health care providers. Nevertheless there are variations between the regions in the proportion of prescribed courses of mefloquine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661472     DOI: 10.1023/a:1022474225270

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  8 in total

1.  On achieving consensus on the prevention of malaria.

Authors:  C J Ellis
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

2.  [Malaria prevention: recommendations adapted once more. Work Group Malaria Prophylaxis].

Authors: 
Journal:  Ned Tijdschr Geneeskd       Date:  1996-04-20

3.  Tolerability of prophylactic Lariam regimens.

Authors:  E Boudreau; B Schuster; J Sanchez; W Novakowski; R Johnson; D Redmond; R Hanson; L Dausel
Journal:  Trop Med Parasitol       Date:  1993-09

4.  [Malaria prophylaxis: recommendations adapted again].

Authors:  W M Dolmans; H J van der Kaay; A Leentvaar-Kuijpers; P C Stuiver; J C Wetsteyn; A A Warris-Versteegen
Journal:  Ned Tijdschr Geneeskd       Date:  1994-08-20

5.  Update on prevention of malaria for travelers.

Authors:  H O Lobel; P E Kozarsky
Journal:  JAMA       Date:  1997-12-03       Impact factor: 56.272

Review 6.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

7.  [Malaria prophylaxis; advice for the individual traveller. The Working Group for Malaria Prophylaxis].

Authors: 
Journal:  Ned Tijdschr Geneeskd       Date:  1998-04-18

Review 8.  Malaria in travellers: epidemiology and prevention.

Authors:  R H Behrens; C F Curtis
Journal:  Br Med Bull       Date:  1993-04       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.